Health Dictionary Find a Doctor

Generalized anxiety disorder

For patient information click here

Template:DiseaseDisorder infobox

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Irfan Dotani

Synonyms and keywords: GAD; anxiety

Overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Irfan Dotani

Overview

Generalized anxiety disorder (GAD) is an anxiety disorder that is characterized by excessive, uncontrollable and often irrational worry about everyday things, which is disproportionate to the actual source of worry. This excessive worry often interferes with daily functioning, as individuals suffering from GAD typically catastrophize, anticipate disaster, and are overly concerned about everyday matters such as health issues, money, family problems, or work difficulties.[1] They often exhibit a variety of physical symptoms, including fatigue, headaches, muscle tension, muscle aches, difficulty swallowing, trembling, twitching, irritability, sweating, and hot flashes. These symptoms must be consistent and on-going, persisting at least 6 months, for a formal diagnosis of GAD to be introduced. [1] Approximately 6.8 million American adults experience GAD, affecting about twice as many women as men.[2]

Historical Perspective

Generalized anxiety disorder was first recognized as a symptom by Sigmund Freud. In 1980, ‘The American Psychiatric Association’ introduced GAD as a diagnosis in the DSM-III.

Classification

Generalized anxiety disorder falls under the category of anxiety disorder.[3]

Pathophysiology

Generalized anxiety disorder has been linked to the disrupted functional connectivity of the amygdala and its processing of fear and anxiety.[4]

Differentiating Generalized anxiety disorder from other Disorders

The differential diagnosis in generalized anxiety disorder is similar to that of panic disorder. It is important to rule out drug-induced conditions. The mental status examination should take in consideration the possibility of schizophrenia, obsessive-compulsive disorder, major depressive disorder, and both specific and social phobias.

Epidemiology and Demographics

Generalized anxiety disorder is relatively common and has a lifetime prevalence of about 4-7% in the general population. It is more common in women, and can develop in any age although it more commonly occurs in the third and fourth decade of life. Approximately one quarter of the patients with generalized anxiety disorder, will develop panic disorder.

Risk Factors

Risk factors for developing generalized anxiety disorder include family history, early adulthood, and a recent life stressor.

History and Symptoms

The criteria for generalized anxiety disorder include at least 6 months of excessive anxiety or worry, about a number of situations, which is difficult to control. The worry may also be associated with three of the following symptoms; restlessness. fatigue, irritability, muscle tension, poor sleep, and difficulty concentrating. There are several disorders that have a tendency to co-occur with generalized anxiety disorder. These include; major depressive disorder, panic disorder, social phobia, agoraphobia, substance abuse, irritable bowel syndrome and sleep disorders.

Natural history, Complications, and Prognosis

In the National Comorbidity Survey (2005), 58% of patients diagnosed with major depression were found to have an anxiety disorder; among these patients, the rate of comorbidity with GAD was 17.2%, and with panic disorder, 9.9%.

Diagnostic Criteria

The criteria for generalized anxiety disorder include at least 6 months of excessive anxiety or worry, about a number of situations, which is difficult to control. The worry may also be associated with three of the following symptoms; restlessness. fatigue, irritability, muscle tension, poor sleep, and difficulty concentrating.

History and Symptoms

There are several disorders that have a tendency to co-occur with generalized anxiety disorder. These include; major depressive disorder, panic disorder, social phobia, agoraphobia, substance abuse, irritable bowel syndrome and sleep disorders.

Laboratory Findings

There are no laboratory findings associated with generalized anxiety disorder.

Other Imaging Findings

There are no other imaging findings associated with generalized anxiety disorder.

Other Diagnostic Studies

There are no other diagnostic studies associated with generalized anxiety disorder.

Medical Therapy

There are a variety of medications which can be used to treat generalized anxiety disorder, and they generally work well particularly in conjunction with psychotherapy. The first line treatments are the SSRI class of antidepressants such as fluoxetine, paroxetine, and escitalopram. Other antidepressants such as imipramine, venlafaxine, and buspirone may also be effective. Benzodiazepines provide quick, effective relief from anxiety, however must be prescribed with caution due to a high risk of abuse and dependence.

Psychotherapy

A psychological method of treatment for GAD is cognitive behavioral therapy (CBT), which involves a therapist working with the patient to understand how thoughts and feelings influence behavior.[5] The goal of the therapy is to change negative thought patterns that lead to the patient’s anxiety, replacing them with positive, more realistic ones. Elements of the therapy include exposure strategies to allow the patient to gradually confront their anxieties and feel more comfortable in anxiety-provoking situations, as well as to practice the skills they have learned. CBT can be used alone or in conjunction with medication.


Neuroscience education may reduce catastrophizing among patients with chronic musculoskeletal pain[6].

Brain Stimulation Therapy

There is no FDA approved brain stimulation therapy available for generalized anxiety disorder.

References

  1. 1.0 1.1 “Anxiety Disorders”, National Institute of Mental Health. Accessed 28 May 2008.
  2. “The Numbers Count”, National Institute of Mental Health. Accessed 28 May 2007.
  3. Keeton CP, Kolos AC, Walkup JT (2009). “Pediatric generalized anxiety disorder: epidemiology, diagnosis, and management”. Paediatr Drugs. 11 (3): 171–83. doi:10.2165/00148581-200911030-00003. PMID 19445546.
  4. Etkin A, Prater KE, Schatzberg AF, Menon V, Greicius MD (2009). “Disrupted amygdalar subregion functional connectivity and evidence of a compensatory network in generalized anxiety disorder”. Arch Gen Psychiatry. 66 (12): 1361–72. doi:10.1001/archgenpsychiatry.2009.104. PMID 19996041.
  5. “A Guide to Understanding Cognitive and Behavioural Psychotherapies”, British Association of Behavioural and Cognitive Psychotherapies. Accessed 29 May 2007.
  6. Siddall B, Ram A, Jones MD, Booth J, Perriman D, Summers SJ (2022). “Short-term impact of combining pain neuroscience education with exercise for chronic musculoskeletal pain: a systematic review and meta-analysis”. Pain. 163 (1): e20–e30. doi:10.1097/j.pain.0000000000002308. PMID 33863860 Check |pmid= value (help).
Historical Perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Irfan Dotani

Overview

Generalized anxiety disorder was first recognized as a symptom by Sigmund Freud. In 1980, ‘The American Psychiatric Association’ introduced GAD as a diagnosis in the DSM-III.

Historical Perspective

  • In 1980, ‘The American Psychiatric Association’ introduced GAD as a diagnosis in the DSM-III.
    • Anxiety neurosis was split into:[3]
      • GAD
      • Panic disorder
      • We maintain anxiety through operant conditioning;
        • When we see or encounter something associated with a previous traumatic experience, anxious feelings resurface.
      • We feel temporarily relieved when we avoid situations which make us anxious.
        • This only increases anxious feelings the next time we are in the same position, and we will want to escape the situation again and therefore will not make any progress against the anxiety.

Development of Diagnostic Criteria for Generalized Anxiety Disorder

  • In 1980, DSM-III portrayed GAD as:[4]
  • In 1987, DMS-III-R portrayed GAD as:
    • Unrealistic/excessive anxiety and worry (apprehensive expectation) about 2 or more life circumstances
  • In 1992, ICD-10 portrayed GAD as:
    • Generalized and persistent anxiety, not restricted to or even predominating in any environmental circumstances (ie, “free-floating”)
  • The ICD-11, beta draft, portrayed GAD as:
    • Marked symptoms of anxiety accompanied by either general apprehension (ie, “free-floating anxiety”) or worry focused on multiple everyday events (family, health, finances, school, or work)
  • In 1994, DSM-IV portrayed GAD as:
    • Excessive anxiety and worry (apprehensive expectation) about a number of events or activities
    • Difficult to control the worry
  • In 2013, DSM-V portrayed GAD as:

References

  1. Kessler RC, Keller MB, Wittchen HU (2001). “The epidemiology of generalized anxiety disorder”. Psychiatr Clin North Am. 24 (1): 19–39. PMID 11225507.
  2. Crocq MA (2017). “The history of generalized anxiety disorder as a diagnostic category”. Dialogues Clin Neurosci. 19 (2): 107–116. PMC 5573555. PMID 28867935.
  3. Torpy JM, Burke AE, Golub RM (2011). “JAMA patient page. Generalized anxiety disorder”. JAMA. 305 (5): 522. doi:10.1001/jama.305.5.522. PMID 21285432.
  4. Wittchen HU, Kessler RC, Zhao S, Abelson J (1995). “Reliability and clinical validity of UM-CIDI DSM-III-R generalized anxiety disorder”. J Psychiatr Res. 29 (2): 95–110. PMID 7666382.
Classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Irfan Dotani

Overview

Generalized anxiety disorder falls under the category of anxiety disorder.

Classification

  • Generalized anxiety disorder falls under the category of anxiety disorder.[1]

References

  1. Keeton CP, Kolos AC, Walkup JT (2009). “Pediatric generalized anxiety disorder: epidemiology, diagnosis, and management”. Paediatr Drugs. 11 (3): 171–83. doi:10.2165/00148581-200911030-00003. PMID 19445546.
Pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Irfan Dotani

Overview

Generalized anxiety disorder has been linked to the disrupted functional connectivity of the amygdala and its processing of fear and anxiety. Sensory information enters the amygdala through the nuclei of the basolateral complex (consisting of lateral, basal and accessory basal nuclei).

Pathophysiology

References

  1. Etkin A, Prater KE, Schatzberg AF, Menon V, Greicius MD (2009). “Disrupted amygdalar subregion functional connectivity and evidence of a compensatory network in generalized anxiety disorder”. Arch Gen Psychiatry. 66 (12): 1361–72. doi:10.1001/archgenpsychiatry.2009.104. PMID 19996041.
  2. Kessler RC, Keller MB, Wittchen HU (2001). “The epidemiology of generalized anxiety disorder”. Psychiatr Clin North Am. 24 (1): 19–39. PMID 11225507.
  3. Baldwin DS, Allgulander C, Bandelow B, Ferre F, Pallanti S (2012). “An international survey of reported prescribing practice in the treatment of patients with generalised anxiety disorder”. World J Biol Psychiatry. 13 (7): 510–6. doi:10.3109/15622975.2011.624548. PMID 22059936.
  4. Grant BF, Hasin DS, Stinson FS, Dawson DA, June Ruan W, Goldstein RB; et al. (2005). “Prevalence, correlates, co-morbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions”. Psychol Med. 35 (12): 1747–59. doi:10.1017/S0033291705006069. PMID 16202187.
Differentiating Generalized Anxiety Disorder from other Diseases

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Charmaine Patel, M.D. [2] Irfan Dotani

Overview

The differential diagnosis in generalized anxiety disorder is similar to that of panic disorder. It is important to rule out drug-induced conditions. The mental status examination should take in consideration the possibility of schizophrenia, obsessive-compulsive disorder, major depressive disorder, and both specific and social phobias.

Differential Diagnosis

Differentiating generalized anxiety disorder from other diseases

Disease Prominent clinical features Investigations
Hyperthyroidism The main symptoms include:[4]
Essential hypertension Most patients with hypertension are asymptomatic at the time of diagnosis. Common symptoms are listed below:[5] JNC 7 recommends the following routine laboratory tests before initiation of therapy for hypertension:
Generalized anxiety disorder According to DSM V, the following criteria should be present to fit the diagnosis of generalized anxiety disorder:
  1. The presence of sense of apprehension or fear toward certain activities for most of the days for at least 6 months
  2. Difficulty to control the apprehension
  3. Associated restless, fatigue, irritability, difficult concentration, muscle tension or sleep disturbance (only one of these manifestations)
  4. The anxiety or the physical manifestations must affect the social and the daily life of the patient
  5. Exclusion of another medical condition or the effect of another administered substance
  6. Exclusion of another mental disorder causing the symptoms
Menopause The perimenopausal symptoms are caused by an overall drop, as well as dramatic but erratic fluctuations, in the levels of estrogens, progestin, and testosterone. Some of these symptoms such as formication etc may be associated with the hormone withdrawal process.
  • B-HCG should always be done first to rule out pregnancy especially in women under the age of 45 years
  • FSH can be measured but it can be falsely normal or low
  • TSH, T3 and T4 to rule out thyroid abnormalities
  • Prolactin can be measured to rule out prolactinoma as a cause of menopause
Opioid withdrawal disorder According to DSM V, the following criteria should be present to fit the diagnosis of opioid withdrawal:[6]
  1. Cessation of (or reduction in) opioid use that has been heavy and prolonged (i.e.,several weeks or longer) or administration of an opioid antagonist after a period of opioid use.
  2. Development of three or more of the following criteria minutes to days after cessation of drug use: dysphoric mood, nausea or vomiting, muscle aches, Lacrimation or rhinorrhea, pupillary dilation, piloerection, or sweating, diarrhea, yawning, fever, and insomnia.
  3. The signs or symptoms mentioned above must cause impairment of the daily functioning of the patient.
  4. The signs or symptoms mentioned above must not be attributed to other medical or mental disorders.
  • Urine drug screen to rule out any other associated drug abuse
  • Routine blood work such as electrolytes and hemoglobin to rule out any associated disease explaining the symptoms
Pheochromocytoma The hallmark symptoms of a pheochromocytoma are those of sympathetic nervous system hyperactivity, symptoms usually subside in less than one hour and they may include:
  • Palpitations especially in epinephrine producing tumors.
  • Anxiety often resembling that of a panic attack
  • Sweating
  • Headaches occur in 90 % of patients.
  • Paroxysmal attacks of hypertension but some patients have normal blood pressure.
  • It may be asymptomatic and discovered by incidence screening especially MEN patients.

Please note that not all patients with pheochromocytoma experience all classical symptoms.

Diagnostic lab findings associated with pheochromocytoma include:
Social phobia The main symptoms include:
  • Anxiety or persistent fear is limited to social situations and fear of social scrutiny or embarrassment.
  • Avoidance behavior commonly present.
  • No differentiating tests exist.
OCD The main symptoms include:
  • No differentiating tests exist.
PTSD The main symptoms include:
  • Anxiety is directly related to exposure to reminders of past trauma; patients re-experience symptoms (through flashbacks, nightmares).
  • No differentiating tests exist.
Somatoform disorders The main symptoms include:
  • Anxiety is directly related to specific physical complaints.
  • Thorough medical evaluation shows no basis for physical complaints.
  • No differentiating tests exist.
Depression The main symptoms include:
  • Inability to feel pleasure with an overall sad or irritable mood.
  • No differentiating tests exist.
Substance-or drug-induced anxiety disorder The main symptoms include:
CNS-depressant withdrawal The main symptoms include:
  • Anxiety may occur during withdrawal of a substance (e.g., alcohol, opioids, sedative-hypnotics) with characteristic symptoms such as shakiness (i.e., rapid heart rate, fluctuating blood pressure), and, if delirium is present, mental confusion.
  • Typical signs are tachypnea, tachycardia, and disorientation.
  • Monitoring of vital signs is essential to detect autonomic instability and sometimes delirium.
Anorexia nervosa The main symptoms include:
  • Anxiety is directly related to a fear of gaining weight.
  • Body weight <85% of ideal.
  • No differentiating tests exist.

References

  1. 1.0 1.1 1.2 Diagnostic and statistical manual of mental disorders : DSM-5. Washington, D.C: American Psychiatric Association. 2013. ISBN 0890425558.
  2. Moffitt TE, Harrington H, Caspi A, Kim-Cohen J, Goldberg D, Gregory AM; et al. (2007). “Depression and generalized anxiety disorder: cumulative and sequential comorbidity in a birth cohort followed prospectively to age 32 years”. Arch Gen Psychiatry. 64 (6): 651–60. doi:10.1001/archpsyc.64.6.651. PMID 17548747.
  3. Wolitzky-Taylor KB, Castriotta N, Lenze EJ, Stanley MA, Craske MG (2010). “Anxiety disorders in older adults: a comprehensive review”. Depress Anxiety. 27 (2): 190–211. doi:10.1002/da.20653. PMID 20099273.
  4. Smith JP, Book SW (2010). “Comorbidity of generalized anxiety disorder and alcohol use disorders among individuals seeking outpatient substance abuse treatment”. Addict Behav. 35 (1): 42–5. doi:10.1016/j.addbeh.2009.07.002. PMC 2763929. PMID 19733441.
  5. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE (2005). “Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication”. Arch Gen Psychiatry. 62 (6): 617–27. doi:10.1001/archpsyc.62.6.617. PMC 2847357. PMID 15939839. Review in: Evid Based Ment Health. 2006 Feb;9(1):27
  6. Keeton CP, Kolos AC, Walkup JT (2009). “Pediatric generalized anxiety disorder: epidemiology, diagnosis, and management”. Paediatr Drugs. 11 (3): 171–83. doi:10.2165/00148581-200911030-00003. PMID 19445546.
Epidemiology and Demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Charmaine Patel, M.D. [2] Irfan Dotani

Overview

Generalized anxiety disorder is relatively common and has a lifetime prevalence of 900 per 100,000 (0.9%) in adolescents and 2,900 per 100,000 (2.9%) in adults.[1] It is more common in women, and can develop in any age although it more commonly occurs in the third and fourth decade of life.

Epidemiology and Demographics

Prevalence

  • The 12-months prevalence in overall population is:
    • 900 per 100,000 (0.9%) in adolescents
    • 2,900 per 100,000 (2.9%) in adults[1]
  • The World Health Organization‘s Global Burden of Disease project did not include generalized anxiety disorders.[2] In lieu of global statistics, here are some prevalence rates from around the world:
    • Australia: 3 percent of adults[2]
    • Canada: Between 3-5 percent of adults[3]
    • Italy: 2.9 percent[4]
    • Taiwan: 0.4 percent[4]
    • United States: approx. 3.1 percent of people age 18 and over in a given year (6.8 million)

Age

  • The disorder most commonly has its onset in the third decade of life, and mostly occurs in persons under the age of 30 years old. Generalized anxiety disorder can be seen at any age.

Gender

  • Generalized anxiety disorder is more commonly seen in females. This may partly be due to the increased tendency of women to report symptoms.

Race

  • Generalized anxiety disorder is more common in African Americans.

References

  1. 1.0 1.1 Diagnostic and statistical manual of mental disorders : DSM-5. Washington, D.C: American Psychiatric Association. 2013. ISBN 0890425558.
  2. 2.0 2.1 “Relating the burden of anxiety and depression to effectiveness of treatment”, World Health Organization.
  3. http://www.canmat.org/resources/depression/gad.html
  4. 4.0 4.1 http://www.emedicine.com/med/byname/anxiety-disorders.htm
Risk Factors

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Irfan Dotani

Overview

Risk factors for developing generalized anxiety disorder include a positive family history, early adulthood, and a recent life stressor. Genetics along with substance-induced anxiety are large factors as well.

Risk Factors

Risk factors for generalized anxiety disorder include:[1]

Genetics

  • Genes are attributed to about 33% of general anxiety disorder’s variance.[2]
  • Individuals with a genetic predisposition for GAD are more likely to develop GAD.
    • Especially in response to a life stressor.[3]

Substance-Induced

  • Anxiety can be worsened through the use of benzodiazepines.[4]
    • Benzodiazepines can lead to a lessening of anxiety symptoms.
  • Similarly, long-term alcohol use is associated with anxiety disorders
    • Prolonged abstinence can result in a disappearance of anxiety symptoms.
  • It can take up to two years for anxiety symptoms to return to baseline in about a quarter of people recovering from alcoholism.
  • Tobacco smoking has been established as a risk factor for developing anxiety disorders.[5]
  • Excessive caffeine use has been linked to anxiety.

Case Studies

  • In 1988–90, illness in approximately half of the patients attending mental health services at British hospital psychiatric clinic, for conditions including anxiety disorders such as panic disorder or social phobia, was determined to be the result of alcohol or benzodiazepine dependence.[6]
    • In these patients, anxiety symptoms, while worsening initially during the withdrawal phase, disappeared with abstinence from benzodiazepines or alcohol.
  • Sometimes anxiety, pre-existed alcohol, or benzodiazepine dependence, keep anxiety disorders going and often progressively making them worse.
    • Recovery from benzodiazepines tends to take a lot longer than recovery from alcohol, but people can regain their previous good health.[7]

References

  1. Diagnostic and statistical manual of mental disorders : DSM-5. Washington, D.C: American Psychiatric Association. 2013. ISBN 0890425558.
  2. Hettema JM, Neale MC, Kendler KS (2001). “A review and meta-analysis of the genetic epidemiology of anxiety disorders”. Am J Psychiatry. 158 (10): 1568–78. doi:10.1176/appi.ajp.158.10.1568. PMID 11578982. Review in: Evid Based Ment Health. 2002 Aug;5(3):92
  3. Donner J, Pirkola S, Silander K, Kananen L, Terwilliger JD, Lönnqvist J; et al. (2008). “An association analysis of murine anxiety genes in humans implicates novel candidate genes for anxiety disorders”. Biol Psychiatry. 64 (8): 672–80. doi:10.1016/j.biopsych.2008.06.002. PMC 2682432. PMID 18639233.
  4. Cohen SI (1995). “Alcohol and benzodiazepines generate anxiety, panic and phobias”. J R Soc Med. 88 (2): 73–7. PMC 1295099. PMID 7769598.
  5. Morissette SB, Tull MT, Gulliver SB, Kamholz BW, Zimering RT (2007). “Anxiety, anxiety disorders, tobacco use, and nicotine: a critical review of interrelationships”. Psychol Bull. 133 (2): 245–72. doi:10.1037/0033-2909.133.2.245. PMID 17338599.
  6. Ashton H (2005). “The diagnosis and management of benzodiazepine dependence”. Curr Opin Psychiatry. 18 (3): 249–55. doi:10.1097/01.yco.0000165594.60434.84. PMID 16639148.
  7. Bruce MS, Lader M (1989). “Caffeine abstention in the management of anxiety disorders”. Psychol Med. 19 (1): 211–4. PMID 2727208.
Natural History, Complications and Prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Irfan Dotani

Overview

In the National Comorbidity Survey (2005), 58% of patients diagnosed with major depression were found to have an anxiety disorder. Accumulating evidence indicates that patients with comorbid depression and anxiety tend to have greater illness severity and a lower treatment response than those with either disorder alone. In addition, social function and quality of life are more greatly impaired. Approximately one-quarter of the patients with generalized anxiety disorder, will develop panic disorder.

Natural History, Complications and Prognosis

  • In the National Comorbidity Survey (2005), 58% of patients diagnosed with major depression were found to have an anxiety disorder; among these patients, the rate of comorbidity with GAD was 17.2%, and with panic disorder, 9.9%.
  • Patients with a diagnosed anxiety disorder also had high rates of comorbid depression, including 22.4% of patients with social phobia, 9.4% with agoraphobia, and 2.3% with panic disorder.[1]
    • For many, the symptoms of both depression and anxiety are not severe enough (i.e. are subsyndromal) to justify a primary diagnosis of either major depressive disorder (MDD) or an anxiety disorder.
  • Patients can also be categorized as having mixed anxiety-depressive disorder, and they are at significantly increased risk of developing full-blown depression or anxiety. Appropriate treatment is necessary to alleviate symptoms and prevent the emergence of more serious disease.[2]
  • Accumulating evidence indicates that patients with comorbid depression and anxiety tend to have greater illness severity and a lower treatment response than those with either disorder alone. In addition, social function and quality of life are more greatly impaired.
  • Patients with physical symptoms such as insomnia or headaches should also tell their doctors about their feelings of worry and tension.[3]
    • This will help the patient’s health care provider to recognize whether the person is suffering from GAD.
  • Approximately one-quarter of the patients with generalized anxiety disorder, will develop panic disorder.[4]

References

  1. Morissette SB, Tull MT, Gulliver SB, Kamholz BW, Zimering RT (2007). “Anxiety, anxiety disorders, tobacco use, and nicotine: a critical review of interrelationships”. Psychol Bull. 133 (2): 245–72. doi:10.1037/0033-2909.133.2.245. PMID 17338599.
  2. Kessler RC, Keller MB, Wittchen HU (March 2001). “The epidemiology of generalized anxiety disorder”. Psychiatr. Clin. North Am. 24 (1): 19–39. PMID 11225507.
  3. Newman MG, Przeworski A, Fisher AJ, Borkovec TD (2010). “Diagnostic comorbidity in adults with generalized anxiety disorder: impact of comorbidity on psychotherapy outcome and impact of psychotherapy on comorbid diagnoses”. Behav Ther. 41 (1): 59–72. doi:10.1016/j.beth.2008.12.005. PMC 2827339. PMID 20171328.
  4. Shalev I, Moffitt TE, Braithwaite AW, Danese A, Fleming NI, Goldman-Mellor S; et al. (2014). “Internalizing disorders and leukocyte telomere erosion: a prospective study of depression, generalized anxiety disorder and post-traumatic stress disorder”. Mol Psychiatry. 19 (11): 1163–70. doi:10.1038/mp.2013.183. PMC 4098012. PMID 24419039.
Diagnosis

Diagnosis

Diagnostic Criteria | History and Symptoms | Laboratory Findings | Other Imaging Findings | Other Diagnostic Studies


Treatment

Treatment

Medical Therapy | Psychotherapy| Brain Stimulation Therapy

Case Studies

Case Studies

Case #1

Template:WH Template:WikiDoc Sources

Looking for the patient version?

Back to the patient-friendly article

© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH